COVID-19 | Mild disease, no severity among Indian patients: INSACOG on Omicron's XBB variant

Expert panel says XBB variant of COVID-19 has been detected in multiple States in the country

November 02, 2022 03:57 pm | Updated 04:22 pm IST - New Delhi

Image for representation purpose only.

Image for representation purpose only. | Photo Credit: Reuters

Indian patients infected with Omicron sub-lineage XBB of COVID-19 have mild disease and no increase in severity is noted, the INSACOG said.

The expert panel said the XBB variant has been detected in multiple States in the country.

Data | Omicron variant BA.2 and its sub-lineages responsible for latest COVID-19 surge

The Indian SARS-CoV-2 Genomics Consortium (INSACOG), in a statement, said it is keeping a close watch and monitoring the emergence and evolution of XBB and XBB.1 and any new sub-lineages.

“The community need not panic and adherence to coronavirus appropriate behaviour is recommended in the light of ongoing festivities,” it said.

Among the Indian patients the disease is mild like with other Omicron sub-lineages and no increase in severity is noted, the panel said.

Also read: Researchers claim new COVID-19 test CoVarScan can identify all variants in hours

In the current phase of the pandemic, the INSACOG said the SARS-CoV-2 virus is continuously accumulating mutations, some of which might contribute to increased transmissibility and immune evasion resulting in transmission advantage over other variants.

“XBB, a BJ.1/BM.1.1.1 recombinant lineage with breakpoint in the spike protein is presently appearing in multiple countries. This recombinant lineage was first detected in Singapore and the U.S., and has also been identified in multiple States in India,” it said.

A sub-lineage of XBB with an additional mutation is also detected (XBB.1).

“Modest increase in the spread of XBB in Singapore has been observed. However, there has been no report of increase in severity of disease or increase in hospitalisation associated with these variants,” it added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.